Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Jolanda Howe Sells 968 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 968 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $103.30, for a total value of $99,994.40. Following the transaction, the senior vice president owned 4,503 shares in the company, valued at approximately $465,159.90. The trade was a 17.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Jolanda Howe also recently made the following trade(s):

• On Monday, January 26th, Jolanda Howe sold 842 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $96.19, for a total value of $80,991.98.
• On Thursday, January 22nd, Jolanda Howe sold 926 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $93.33, for a total transaction of $86,423.58.

Mirum Pharmaceuticals Trading Up 1.6%

NASDAQ:MIRM opened at $105.45 on Wednesday. The firm has a market capitalization of $5.42 billion, a P/E ratio of -122.61 and a beta of 0.49. Mirum Pharmaceuticals, Inc. has a 52 week low of $36.88 and a 52 week high of $105.64. The company has a quick ratio of 3.16, a current ratio of 3.31 and a debt-to-equity ratio of 1.06. The company has a fifty day moving average of $81.60 and a 200 day moving average of $73.33.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.15. The firm had revenue of $133.01 million for the quarter, compared to analysts’ expectations of $130.11 million. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. The company’s revenue for the quarter was up 47.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.30) earnings per share. On average, research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several hedge funds have recently bought and sold shares of the business. MCF Advisors LLC lifted its holdings in shares of Mirum Pharmaceuticals by 76.4% during the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after purchasing an additional 185 shares during the last quarter. Quantbot Technologies LP purchased a new position in Mirum Pharmaceuticals during the third quarter valued at $33,000. Quarry LP bought a new stake in Mirum Pharmaceuticals in the third quarter worth $41,000. CWM LLC grew its stake in shares of Mirum Pharmaceuticals by 30.8% in the third quarter. CWM LLC now owns 683 shares of the company’s stock worth $50,000 after acquiring an additional 161 shares during the last quarter. Finally, Comerica Bank grew its stake in shares of Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after acquiring an additional 278 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Stifel Nicolaus lifted their price objective on Mirum Pharmaceuticals from $92.00 to $98.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Citigroup reiterated an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Friday, December 19th. JMP Securities set a $95.00 price objective on shares of Mirum Pharmaceuticals in a research report on Wednesday, November 5th. TD Cowen reaffirmed a “buy” rating on shares of Mirum Pharmaceuticals in a research report on Monday, January 12th. Finally, Wall Street Zen raised shares of Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 17th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Mirum Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $107.25.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.